Travere Stock Pops After Snagging Full Approval For Calliditas Rival In Kidney Disease
Investor's Business DailyTravere Therapeutics stock surged Friday after the biotech company snagged full FDA approval for its kidney disease treatment, Filspari.
The post Travere Stock Pops After Snagging Full Approval For Calliditas Rival In Kidney Disease appeared first on I…